Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMarin Pharmaceutical has announced that AnGes, the company's marketing and distribution partner in Japan, has received approval for its marketing application for Naglazyme from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with mucopolysaccharidosis VI.
Subscribe to our email newsletter
BioMarin established a marketing and distribution agreement with AnGes in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market. AnGes submitted a marketing application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2007. In addition, Naglazyme obtained orphan designation in June 2007 from the MHLW in Japan.
Stephen Aselage, senior vice president of global commercial development at BioMarin, said: “We are proud to work with AnGes in bringing the first drug treatment option to MPS VI patients in Japan.”